May 26, 2026
Hype, Hope, and a Faceplant
The Ballad of TIGIT
Cancer drug dream crashes as commenters cheer the risk, roast the hype, and ask what TIGIT even means
TLDR: TIGIT was supposed to be the next huge cancer-drug breakthrough, but it now looks like another expensive miss. Commenters were split between defending risky medical bets, roasting overhyped science, and hilariously demanding someone finally explain what “TIGIT” actually stands for.
The real action here isn’t just that TIGIT, a once-hyped cancer drug idea, appears to have flopped after years of hope and huge spending. It’s that the comments instantly turned into a mini town hall on how modern medicine burns cash, chases miracle cures, and still somehow keeps everyone emotionally invested. The article paints TIGIT as pharma’s latest “next Keytruda” fantasy — a drug class meant to copy the success of blockbuster cancer treatments by taking the brakes off the immune system — only to end up looking more like another expensive dead end.
And commenters had feelings. One camp was surprisingly calm: yes, this failed, but that’s the price of taking big swings if you want life-saving breakthroughs. Another camp came in swinging harder, dragging past Alzheimer’s research and bluntly calling the amyloid theory “academic fraud,” which definitely turned the temperature up. Then there were the realists, pointing out that while one shiny target dies, another long-shot target — KRAS, once dubbed “undruggable” — is suddenly working, proving that today’s joke can become tomorrow’s jackpot.
But the funniest low-key drama? A reader basically rage-posted: how do you write ‘TIGIT’ 40 times and never explain what the letters stand for? That tiny complaint may have been the most relatable moment in the whole thread. In other words: science tragedy, comment-section comedy, and a lot of side-eye about how the drug hype machine works.
Key Points
- •The article presents TIGIT drugs as a major cancer immunotherapy class that followed a trajectory of high expectations and later disappointment.
- •It links industry enthusiasm for TIGIT to the success of Keytruda (pembrolizumab), approved in 2014, which validated checkpoint-based cancer immunotherapy.
- •TIGIT is described as a protein thought to function as an immune-system brake that tumors may exploit to suppress immune responses.
- •Roche is identified as an early leader in TIGIT research, publishing a 2014 paper and developing tiragolumab, the first anti-TIGIT drug.
- •The article says tiragolumab’s clinical debut came at ASCO 2020 with a 135-patient phase 2 trial in metastatic non-small-cell lung cancer.